A screening system is described that can detect and confirm inhibitors of the late steps of gene from Citrobacter freundii on a plasmid. Positive samples were detected from compound libraries, from natural products libraries, and from fractions of natural products crude preparations. These samples were then subjected to in vitro assays that could detect the incorporation of soluble cell wall precursor into Lipid I, Lipid II, and polymerized cell wall, using a TLC system that was very accurate and unambiguous in detecting known cell wall inhibitors. One partially purified sample containing a novel antibacterial agent derived from whereas another partially purified sample also derived from natural products inhibited proved to be especially useful because it was sufficiently sensitive and robust to detect inhibitors among samples of crude preparations or varying states of purity. In order to detect inhibitors of the late cell wall reactions, we refined the assays for detecting these biosynthetic steps by developing thin layer chromatography assays, called TLC System I and TLC System II. These assays could detect products from radioactive substrates and could measure the quantitative effect of inhibitors of these reactions. However, because the enzyme source for these assays was a particulate fraction, in common with other assays of these cell wall reactions that have been described5-7), TLC Systems I and II were not amenable to high-throughput screening. Therefore a two-step strategy
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Enzymes and structures involved in cell wall biosynthesis have proved to be excellent targets for antibacterial agents because the cell wall pathway is conserved among bacterial pathogens and is absent from mammalian cells. Inhibitors of several steps in cell wall biosynthesis have been identified, and more than forty cell wall active agents have been approved for clinical use1).
The early steps in cell wall synthesis lead to the formation of the soluble precursor, UDP-muramyl-pentapeptide. The late steps involve the formation of the lipid-bound intermediates (Lipid I and Lipid II), transglycosylation into the polymeric chain, and transpeptidation, resulting in cross-links between chains1-4). Because of the membranebound nature of the reactions that occur late in the pathway, the late steps are more difficult to screen for biochemically, whereas biochemical screening of the early steps in wall biosynthesis have been described previously1). Our goal was to identify novel compounds that inhibit the late stage reactions leading to incorporation into the cell wall polymer. Our screening strategy allowed for the detection of inhibitors of the formation of Lipid I (carried out by the MraY protein), Lipid II (carried out by MurG), and transglycosylation (catalyzed by the large penicillin binding proteins).
In order to detect inhibitors of the late cell wall reactions, we refined the assays for detecting these biosynthetic steps by developing thin layer chromatography assays, called TLC System I and TLC System II. These assays could detect products from radioactive substrates and could measure the quantitative effect of inhibitors of these reactions. However, because the enzyme source for these assays was a particulate fraction, in common with other assays of these cell wall reactions that have been described5-7), TLC Systems I and II were not amenable to high-throughput screening. Therefore a two-step strategy lactamase induction screen that was capable of detecting activities that affected either early or late steps in cell wall biosynthesis8). The small minority of samples that tested subjected to the assays described here, which could detect late stage inhibitors and pinpoint the inhibited step.
Both chemical and natural products files were sources for active compounds. The partial characterization of two compound classes derived from natural products are described, one which inhibits the formation of Lipid I and the other which prevents transglycosylation.
Materials and Methods
Samples were tested for cell wall activity as described8). muramyl-pentapeptide), and the peptidoglycan product (found at the origin) were quantified by measuring the intensity of the appropriate spot after obtaining an image with a digital camera.
TLC System II Assay to Distinguish MraY and MurG
Inhibitors
The membrane preparation was described in TLC system I. The substrates are the same as in TLC System I except that UDP-GlcNAc is excluded from the reaction mixture, and UDPMurNAc-14C-DAP-pentapeptide (provided by Dr. TED PARK, Tufts University) was the radiolabeled substrate.
added, and the reaction proceeded for 30 minutes. The reaction was arrested by boiling for 1 minute. The TLC protocol and the data computation for quantifying the formation of Lipid I (undecaprenyl-P-P-N-acetylmuramylpentapeptide covalently linked to the C55 isoprenoid (undecaprenyl-phosphate)), were as described above for TLC Assay System I. 
LC-MS Analysis of Natural Products Extracts
Extracts of active fermentation broths were treated and analyzed by suspending in a mixture of methanol/water (1: 1 v/v), filtered, and subjected to HPLC as described9), using conditions detailed previously10). vancomycin, completely inhibited the formation of transglycosylation (no spot at the origin), but had no effect on Lipid II formation.
TLC System II Specifically Assays Lipid I Formation
In the case of ramoplanin, the TLC System I, described above, did not distinguish if Lipid I or Lipid II formation was inhibited, because the migration distance of Lipid I and Lipid II were equivalent, and UDP-GlcNAc, which is a substrate for Lipid II formation, contained the radioactive label. In order to differentiate inhibitors of Lipid I and Lipid II formation, the TLC System II was developed.
Samples were incubated with the particulate enzyme preparation as before, except that in TLC System II, labeled UDP-muramylpentapeptide was the only substrate in the reaction. Because UDP-GlcNAc was absent, the substrate could only be converted to Lipid I by the particulate enzyme preparation (Figure 2 ). In the presence of Induction Value threshold was set at 0.2 (sufficient to detect 5% of the induction of fully induced cells8)), then 1.03% of samples tested positive among more than 100,000 chemicals which were tested. The retest frequency was 54%. Among the positive compounds were moenomycin, avoparcin, and bacitracin, which were the control compounds in the file known to have cell wall activity.
The number of samples that were considered for TLC induction screen had been very effective in discriminating against compounds with no cell wall inhibitory activity.
Among hundreds of positive samples, 2.5% showed >50% of compound.
Screening Crude Extracts of the Millennium Pharmaceuticals Natural Products Library
The strategy for screening natural products for late stage inhibitors of cell wall synthesis was similar to the approach with the chemical file. The Millennium Pharmaceuticals natural products drug source is derived mostly from fungal fermentations.
The crude extracts were first tested for cell the total of 1008 fungal isolates that were fermented, 170
tested and retested as positive cultures. The 65 cultures that following subsequent fermentations were subjected to fractionation as described in Materials and Methods, and each fraction of the sixty-five was tested for induction activity. Extracts of isolates AA2495 and AA7798, two examples induction screen. Fractionation of the extract of culture AA2549 revealed that fractions 37-42 contained activity in the primary screen. When these fractions were run in TLC System I there was little or no effect on the synthesis of Lipid II, but there was a strong inhibitory effect on the polymerization of precursor into cell wall polymer, suggesting the presence of a transglycosylase activity (Figure 3) . When an extract of isolate AA7798 was tested, it also had strong inducing activity. showed antibacterial activity against Gram-positive microorganisms in the range of its enzymatic inhibitory activity against the Gram-positive bacteria Staphylococcus aureus (data not shown), suggesting that the cell wall activity was the source of its antibacterial activity.
When AA896 was similarly tested in TLC System I, it not only prevented the incorporation label into cell wall polymer, but also inhibited the formation of Lipid II, with an IC50 of 62.5ng/ml (Figure 6 ). To determine whether Lipid I or Lipid II formation was affected, AA896 was run in TLC System II. AA896 showed potent in vitro inhibitory Our strategy was to utilize a cell-based, pathway specific screen as the primary means of identifying candidate effective because it satisfied the following criteria: (1) it was sensitive in detecting a wide variety of compounds that affect all cell wall biosynthetic steps, (2) it was effective in discriminating against most non-cell wall activities, and (3) it had a low background of false positive activities. Thus the concentrated effort could be devoted to the small Figure 1 shows that ramoplanin prevented the formation of both cell wall polymer and Lipid II formation. Figure 2 shows that ramoplanin did not interfere with TLC I formation, and therefore must have inhibited the formation of Lipid II. In fact, Figure 2 shows that ramoplanin actually increased the formation of Lipid I, as has been noted previously5). Taking into account the observation that the Lipid I reaction is reversible5), the most straightforward explanation for the apparent enhancement of Lipid I formation in the presence of ramoplanin is that the compound binds directly with Lipid I, stabilizing its formation, and arresting its conversion to Lipid II. Thus ramoplanin may inhibit cell wall biosynthesis by binding to a cell wall precursor structure, analogous to the action of vancomycin on Lipid II.
The TLC Systems I and II were less effective in detecting inhibitors of isoprenoid recycling, such as bacitracin, which shows a partial inhibition in TLC system I. Apparently the isoprenoid carried out some cycling in the in vitro system, sufficient to detect a partial effect on Lipid II formation (data not shown).
The discovery of activities from extracts of natural products suggests that the late stage reactions of cell wall biosynthesis remain viable targets, despite the fact that the cell wall pathway was the target for the first cell-based screens more than thirty years ago2). The use of a more sensitive pathway specific screen8) may have aided in the detection of activities from the natural products crude and partially purified extracts presented here. The fact that AA896 and AC98 have novel structures (data not shown), provides additional support that novel inhibitors of the late stages of cell wall biosynthesis are still to be discovered.
The development of the TLC Systems I and II assures that candidate samples can be identified as inhibitors of a specific late step of cell wall biosynthesis with accuracy and dependability.
